Filing Flows › Nuvation Bio (NUVB) › License revenue
Nuvation Bio (NUVB) License revenue by quarter
Nuvation Bio's License revenue was $17.5M in Q3 2026 (third quarter 2026), +106% from Q2 2026. Over the last 6 quarters it ranged from $3.6M (Q2 2025) to $64.7M (Q1 2026).
| Quarter | License revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $17.5M | +106% | +224% |
| Q2 2026 | $8.5M | -87% | +136% |
| Q1 2026 | $64.7M | +147% | — |
| Q4 2025 | $26.2M | +385% | — |
| Q3 2025 | $5.4M | +50% | — |
| Q2 2025 | $3.6M | — | — |
Q3 2026 at a glance
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Nuvation Bio's License revenue?
Nuvation Bio's License revenue was $17.5M in Q3 2026 (third quarter 2026), +106% from Q2 2026.
How has Nuvation Bio's License revenue changed?
Over the last 6 quarters it ranged from $3.6M (Q2 2025) to $64.7M (Q1 2026).